KDM4A and neoplasm: Compared with the KDM4C knockdown, the survival of human CD34+ umbilical cord blood cells was rarely affected by knocking down KDM4A. Furthermore, we acquired a series of known and/or potential KDM4 inhibitors for screening, and one of these candidates, SD49-7, impaired LSCs by targeting KDM4A but did not affect normal HSCs both in mice and patient-derived tumor xenograft (PDX) AML models.